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Abstract
Background
The benefits of combination anti-retroviral therapy (cART) in HIV-positive pregnant women
(improved maternal health and prevention of mother to child transmission [pMTCT]) cur-
rently outweigh the adverse effects due to cART. As the variety of cART increases, how-
ever, the question arises as to which type of cART is safest for pregnant women and women
of childbearing age. We studied the effect of timing and exposure to different classes of
cART on adverse birth outcomes in a large HIV cohort in the Netherlands.
Materials and methods
We included singleton HEU infants registered in the ATHENA cohort from 1997 to 2015.
Multivariate logistic regression analysis for single and multiple pregnancies was used to
evaluate predictors of small for gestational age (SGA, birth weight <10th percentile for gesta-
tional age), low birth weight and preterm delivery.
Results
A total of 1392 children born to 1022 mothers were included. Of these, 331 (23.8%) children
were SGA. Women starting cART before conception had an increased risk of having a SGA
infant compared to women starting cART after conception (OR 1.35, 95% CI 1.03−1.77, p =
0.03). The risk for SGA was highest in women who started a protease inhibitor-(PI) based
regimen prior to pregnancy, compared with women who initiated PI-based cART during
pregnancy. While the association of preterm delivery and preconception cART was signifi-
cant in univariate analysis, on multivariate analysis only a non-significant trend was
observed (OR 1.39, 95% CI 0.94−1.92, p = 0.06) in women who had started cART before
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compared to after conception. In multivariate analysis, the risk of low birth weight (OR 1.34,
95% CI 0.94−1.92, p = 0.11) was not significantly increased in women who had started
cART prior to conception compared to after conception.
Conclusion
In our cohort of pregnant HIV-positive women, the use of cART prior to conception, most
notably a PI-based regimen, was associated with intrauterine growth restriction resulting in
SGA. Data showed a non-significant trend in the risk of PTD associated with preconception
use of cART compared to its use after conception. More studies are needed with regard to
the mechanisms taking place in the placenta during fetal growth in pregnant HIV-positive
women using cART. It will only be with this knowledge that we can begin to understand the
potential impact of HIV and cART on the fetus, in order to be able to determine the optimal
individualised drug regimen for HIV-infected women of childbearing age.
Introduction
The benefits of combination anti-retroviral therapy (cART) in HIV-positive pregnant women
(improved maternal health and prevention of mother to child transmission [pMTCT]) currently
outweigh the adverse effects due to cART. As the variety of cART increases, however, the question
arises as to which type of cART is safest for pregnant women and women of childbearing age.
Most cART studies in HIV-positive women and their HIV-exposed uninfected (HEU) infants,
however, have focused on adverse birth outcomes, such as preterm delivery (PTD) and low birth
weight (LBW). As yet, any association between maternal exposure to cART, (including exposure
to protease inhibitors [PI]), and the timing of initiation of cART) and adverse outcomes remains
unclear [1–6]. Furthermore, studies exploring the relationship between cART exposure during
pregnancy and the occurrence of small for gestational age (SGA) births are scarce [7–11], while
studies describing in utero exposure to cART and fetal growth and child development have been
inconclusive. Some studies have found that the use of cART prior to conception increases the risk
of PTD [9, 12, 13] and LBW [5, 14, 15] however, as the definition of LBW is an infant weighing
<2.5 kg, it is not possible to distinguish between preterm and SGA infants.
Evaluating fetal growth is complex, involving the consideration of race, cigarette smoking,
nutritional status, disease stage of HIV and exposure to cART. In the Netherlands, all pregnant
women have equal access to (ante-natal) care and, since 1997, all HIV-positive pregnant
women have been offered cART, usually from the second trimester onwards. Women who
were already receiving cART prior to conception, are encouraged to continue with anti-retro-
viral treatment, unless there are concerns regarding teratogenicity and virological failure, or if
they are unable to tolerate the cART regimen (which may, therefore, need to be modified).
Our objective for this study was to investigate whether or not there may be an association
between different types of cART (and the timing of its initiation) and the occurrence of SGA
in HEU infants.
Materials and methods
Study type
This was a retrospective, observational study; pregnancy-related data were obtained from an
ongoing observational HIV cohort study.
Maternal cART use and small for gestational age
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Population
Data were obtained from the HIV Monitoring Foundation ATHENA cohort database, which
contains records from 1997 onwards, from all HIV-positive women receiving care at any of
the 26 HIV treatment centers in the Netherlands. Written informed consent was obtained
from all of the individuals concerned [16]. Only HIV-positive women (18 years of age) who
gave birth to HEU infants after a minimum of 24 weeks’ pregnancy were eligible for the study.
Singleton live-births (January 1997 to February 2015) were evaluated. This included HIV-posi-
tive women who had started cART comprising at least three antiviral drugs prior to concep-
tion, as well as HIV-positive women who began cART during pregnancy.
For comparison, we used data from the Generation R Study, a multi-ethnic, urban popula-
tion-based prospective cohort study, conducted in Rotterdam, involving HIV-negative women
and their children. Infants were followed from the first trimester of pregnancy up to young
adulthood [17]. The Generation R women were very different to our population in relation to
ethnicity (our population were mostly women from sub-Saharan Africa, SSA), substance
abuse, obstetric follow-up and socioeconomic background. In order to provide a better match
to our population, we only selected SSA women from the Generation R study, to illustrate
growth potential in the Netherlands in children with a similar migration history.
Variables
Baseline data collected from the women’s medical histories included maternal age at delivery,
region of origin (West European, SSA, or other), and cigarette smoking, alcohol and illicit
drug use during pregnancy. Pregnancy- and birth-related data comprised gestational age,
assessed routinely by ultrasound during the first trimester or counted from the first day of the
woman’s last menstrual period, fetal growth at 32 weeks’ gestation, parity and mode of deliv-
ery. Infant-related data comprised gender and birth weight. Medication-related data consisted
of date of cART-initiation, duration of cART, and type of regimen. The women were receiving
cART comprising three different drugs from two pharmacological classes. The clinical labora-
tory measurements comprised CD4+ cell count during pregnancy and closest to delivery (up
to 6 months after delivery), and HIV-RNA during pregnancy, closest to delivery (up to 3
months after delivery).
Self-reporting variables included cigarette smoking, alcohol and illicit drug use. Mode of
delivery was classified as spontaneous vaginal delivery, assisted vaginal delivery and elective or
emergency Caesarean section. SGA was defined as infant birth weight below the 10th percen-
tile, adjusted for gestational age, gender and parity according to Dutch non-Hindustani refer-
ence curves [18]. PTD was defined as birth at<37 weeks’ gestation and very preterm as<32
weeks’ gestation. In keeping with the literature, a birth weight above 2.5 kg was considered
normal, LBW was <2.5 kg and below 1.5 kg was recorded as very low birth weight (VLBW).
Elective Caesarean section in HIV-positive women, in The Netherlands, is usually scheduled at
38 weeks in cases of detectable viremia (virological failure) or late initiation of cART and after
39 weeks for other obstetric indications. An emergency Caesarean delivery was defined as a
Caesarean delivery that was performed after the onset of labour. CD4+ cell count was split into
three categories: <200 cells/μl, 200–500 cells/μl and>500 cells/μl. Plasma HIV-RNA levels
were defined as undetectable at<500 copies/ml (to allow for inter-hospital variation and older
sampling sensitivities).
Study outcomes
The primary outcome was the proportion of HEU infants who were SGA. Secondary outcomes
were: median birth weight (LBW or VLBW), gestational age in weeks, PTD or very PTD).
Maternal cART use and small for gestational age
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Statistical analyses. Mann-Whitney and Chi square tests were used to compare baseline
characteristics. In order to assess the risk of SGA, a logistic regression model including gener-
alized estimating equations (GEE) was used that accounted for multiple pregnancies in one
woman. Independent variables were calculated separately using a univariate binary logistic
regression analysis with GEE. Missing values in the equation were analysed as a group and
taken into the univariate and multivariate models. All individual variables with a p-value of
0.10 in the univariate analyses were included in the multivariate logistic regression analysis.
A probability value of<0.05 was considered statistically significant in the multivariate models.
Statistical analyses were performed using the Statistical Package for Social Sciences version 21
software package for Windows (SPSS Inc, IBM, Chicago, IL, USA) and SAS1 9.3 Software.
Results
Patients
A total of 2184 pregnancies among the HIV-positive women from the ATHENA cohort were
registered between 1997 and 2015. Of these, 619 ended in miscarriage (n = 344; 15.8%), or
elective termination (n = 258; 11.8%) and data were missing for 17 pregnancies. We excluded
23 twin pregnancies. Data on gestational age or birth weight were missing in 48 births, five
births occurred before 24 weeks’ gestation and 82 women were either not using any anti-retro-
viral drugs, or were using an unknown regimen, or a regimen of fewer than three anti-retrovi-
ral drugs. A total of 15 women were<18 years of age when they gave birth.
In total, 1392 singleton births were included in the analysis. cART was used prior to and at
the time of conception by 550 women. A total of 842 women were not using any anti-retroviral
therapy at the time of conception, of whom 625 (74.2%) were cART-naïve and 217 women
(25.8%) had previously received cART. Women who started cART prior to conception had
been receiving cART for a median of 3.48 years (IQR 2.08–5.35).
Baseline maternal characteristics
Baseline demographic, laboratory and treatment characteristics are shown in Table 1. The data
were split into two groups: those women who had started cART prior to conception and those
who had started after conception. In women who began cART after conception, we included
both cART-naive and cART-experienced women who were drug-free at the time of this con-
ception and during the first trimester.
HIV-positive women who started cART prior to conception were older (32.7 vs 28.8 years
of age), more often multiparous (70.2% vs 62.8%), on a non-nucleoside reverse transcriptase
inhibitor- (NNRTI) based regimen (47.8% vs 20.8%) and with a nadir CD4+ cell count of
<200 cells/μl (55.6% vs 22.0%) compared to women who started cART after conception.
Median baseline CD4+ cell count at the start of pregnancy in these HIV-positive women was
similar between the two groups.
Pregnancy outcome
SGA. The SGA rate among the population of HIV-negative women from Generation R
was 1.8%; women from SSA had an SGA rate of 1.4% (S1 Table). In the current study, the over-
all rate of SGA in HEU infants was 23.8% (331/1392) (Table 2). Among the infants of women
who started cART prior to conception, the SGA was 27.3% vs 21.5% in women who started
cART after conception (p = 0.01) (see Table 2). Univariate SGA odds ratio was 1.40 (95% CI
1.11−1.80 p = 0.005) using a GEE. After correcting for cART regimen, region of origin and
parity (variables with p0.1 in the univariate analysis), the risk for SGA was significantly
Maternal cART use and small for gestational age
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Table 1. Baseline characteristics of HIV-negative and HIV-positive women (by group–those starting cART prior to conception and those starting cART after
conception).
HIV-negative
Generation R
HIV-positive women (SHM) P-
Value
n = 9403 (%)
Total
n = 1392 (%)
Preconception
cART
n = 550 (%)
Postconception
cART
n = 842 (%)
Maternal age at childbirth (yrs)
Median 30.45 29.89 32.7 28.8 <0.001
IQR 26.09–33.70 25.75–34.36 28.4–36.3 25.1–33.1
Missing 10 (0.7) 8 (1.5) 2 (0.2)
Region of origin
SSA 900 (9.6) 853 (61.3) 349 (63.5) 504 (59.9)
W. Europe 6207 (66.0) 288 (20.7) 110 (20.0) 178 (21.1) 0.42
Other 2296 (24.4) 251 (18.0) 91 (16.5) 160 (19.0) 0.19
Cigarette smoking status
Yes 1053 (11.2) 114 (8.2) 34 (6.2) 80 (9.5)
No 1935 (20.6) 643 (46.2) 209 (38.0) 434 (51.5) 0.57
Unknown 6415 (68.2) 635 (45.6) 307 (55.8) 328 (39.0) <0.001
Alcohol use
Yes 1190 (12.7) 75 (5.4) 29 (5.3) 46 (5.5)
No 6176 (65.7) 664 (47.7) 208 (37.8) 456 (54.2) 0.20
Unknown 2038 (21.7) 653 (46.9) 313 (56.9) 340 (40.4) <0.001
Illicit drug use
Yes 41 (0.4) 22 (1.6) 6 (1.1) 16 (1.9)
No 8028 (85.4) 706 (50.7) 224 (40.7) 482 (57.2) 0.66
Unknown 1334 (14.2) 664 (47.7) 320 (58.2) 344 (40.9) <0.001
Parity
Primipara 2594 (27.6) 477 (34.3) 164 (29.8) 313 (37.2)
Multipara 6573 (69.9) 915 (65.7) 386 (70.2) 529 (62.8) 0.01
Unknown 236 (2.5)
Mode of delivery
Spontaneous labour 7259 (77.2) 619 (44.5) 198 (36.0) 421 (50.0)
Primary (elective) C-section 419 (4.5) 189 (13.6) 60 (10.9) 129 (15.3) 0.95
Secondary (emergency) C-section 643 (6.8) 198 (14.2) 71 (12.9) 127 (15.1) 0.31
Unknown 1082 (11.5) 386 (27.7) 221 (40.2) 165 (19.6) <0.001
BMI (kg/m2)
Median 23.87 24.9 23.6 25.2 0.07
IQR 21.71–27.06 21.9–28.4 21.4–26.9 22.5–29.1
Unknown 1539 (9.89) 708 (50.9) 339 (61.6) 369 (43.8)
CD4+ (cells/μl)
Median 520 540 510 0.26
IQR 374–700 381.6–720.8 364–690
Missing 24 (1.7) 14 (2.5) 10 (1.2)
Nadir CD4+ (cells/μl)
>500 258 (18.5) 26 (4.7) 232 (27.6)
200–500 643 (46.2) 218 (39.6) 425 (50.5) <0.001
<200 491 (35.3) 306 (55.6) 185 (22.0) <0.001
HIV RNA concentration (copies/ml)
500 1101 (79.1) 484 (88.0) 617 (73.3)
(Continued)
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higher among women who started cART before conception compared to those who only
began cART after conception (1.35, 95% CI 1.03–1.77, p = 0.028) (Table 3). Stratifying for a
PI- or NNRTI-based cART regimen, the multivariate analysis also indicated a significantly
increased risk of SGA among mothers who used a PI-based regimen prior to conception com-
pared with those who had used this regimen only after conception (OR 1.49, 95% CI 1.08
−2.10, p = 0.016) (Table 4). We could not demonstrate this increased risk of SGA among the
infants of women who started a NNRTI-based regimen prior to vs after conception (OR 0.97,
95% CI 0.62−1.52, p = 0.91) (Table 4).
Neonatal birth weight. The median neonatal birth weight from HIV-positive mothers
was 3.09 kg (IQR 2.702−3.405 kg), 0.33 kg lower than the median neonatal birth weight from
(Generation R) HIV-negative mothers (3.42 kg [IQR 3.075−3.770 kg]) but just 0.030 kg lower
Compared to neonates of women originating from sub-Saharan Africa this difference was 30
grams (lower) (S1 Table). The lowest median birth weight was found among the HIV-positive
group of women who had received cART prior to conception (3.07 kg [IQR 2.637−3.384 kg]).
When the type of cART regimen received by the HIV-positive women prior to conception was
taken into consideration (Table 5), those receiving a PI-based regimen had the lowest median
neonatal birth weight (3.02 kg [IQR 2.605−3.365 kg]). LBW (<2.5 kg) was found in 12.4% of
all neonates from HIV-positive women. Among those HIV-positive women who began cART
prior to conception, LBW was found in 14.2% of neonates compared with 11.3% of neonates
in women who had started cART after conception (Table 5). Univariate analysis showed that
the risk of LBW was found to be significantly greater among women who had begun cART
prior to conception (1.35, 95% CI 1.01− 1.80, p = 0.05) compared to those beginning cART
after conception. For the same comparison, but taking into account cigarette smoking, illicit
drug use during pregnancy, parity and gestational age at birth, the risk of LBW was not statisti-
cally different (OR 1.34, (95% CI 0.94−1.92, p = 0.11) between women who started cART prior
to conception vs those who began treatment after conception (S3 Table).
Table 1. (Continued)
HIV-negative
Generation R
HIV-positive women (SHM) P-
Value
n = 9403 (%)
Total
n = 1392 (%)
Preconception
cART
n = 550 (%)
Postconception
cART
n = 842 (%)
>500 272 (19.5) 59 (10.7) 213 (25.3) <0.001
Missing data 19 (1.4) 7 (1.3) 12 (1.4) <0.001
cART regimen
PI-based 928 (66.7) 269 (48.9) 659 (78.3)
NNRTI-based 438 (31.5) 263 (47.8) 175 (20.8) <0.001
Both or NRTI 12 (0.9) 4 (0.7) 8 (1.0) <0.001
 P-values were calculated using Mann-Whitney and Chi square tests
Table 1 abbreviations
SHM: Stichting HIV Monitoring; cART: combination antiretroviral therapy; SSA: Sub-Saharan Africa; W. Europe: Western Europe; IQR: interquartile range; C-section:
Caesarean section; BMI: body mass index; PI: Protease inhibitors; NNRTI: Non-nucleoside reverse-transcriptase inhibitors; Both: both PI- and NNRTI-based regimen;
NRTI: nucleoside reverse transcriptase inhibitors.
HIV-negative (Generation R) Solely to describe the non-HIV population in the Netherlands we selected 9778 children from HIV-negative control women who gave
birth and were included in the Generation R study from 2000 to 2006. Exclusion criteria were a termination of pregnancy (n = 29), intra uterine fetal death (n = 75;
0.7%), HIV-positivity (n = 29), twin pregnancies (n = 262), missing data on birth weight (n = 77), an unknown gestational age (n = 2) or postnatal inclusion (n = 765). A
total of 8539 singleton live births after at least 24 weeks gestation were included in the tables.
https://doi.org/10.1371/journal.pone.0191389.t001
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VLBW (<1.5 kg) occurred in 0.6% of neonates from (Generation R) HIV-negative women,
and in 3.2% of infants from HIV-positive women (S1 Table). Among the HIV-positive women
who started cART prior to conception, VLBW occurred in 4.4% of infants compared with
2.5% of infants from women who started cART after conception (p = 0.02) (Table 2). For the
same comparison (cART initiation prior to and after conception) but corrected for smoking,
illicit drug use during pregnancy, parity and gestational age at birth, the OR for VLBW was
not significantly different between the two groups of women (OR 1.36, 95% CI 0.64−2.90
p = 0.42) (data not shown in the tables).
Preterm delivery. PTD (<37 weeks) occurred in 14.7% of infants from HIV-positive
women, compared with only 5.2% among HIV-negative women (Generation R group); this
percentage was marginally higher among HIV-negative women of SSA origin (5.5%) (S1
Table). PTD was significantly higher among HIV-positive women who began cART prior to
conception (17.5%) compared with those who only began taking cART after conception
Table 2. Outcome of HIV-exposed uninfected (HEU) singleton infants born to HIV-positive mothers by timing of initiation of cART—preconception vs
postconception.
HIV-positive women (SHM) P-
ValueTotal
n = 1392
Preconception
cART
n = 550
Postconception
cART
n = 842
SGA <10th (n, %)
No 1061 (76.2) 400 (72.7) 661 (78.5)
Yes 331 (23.8) 150 (27.3) 181 (21.5) 0.01
SGA <5th (n, %)
No 1199 (86.1) 457 (83.1) 742 (88.1)
Yes 193 (13.9) 93 (16.9) 100 (11.9) 0.01
Median birth weight (kg) 3.090 3.070 3.103 0.22
IQR 2.702−3.405 2.637−3.384 2.754−3.441
Birth weight (n, %)
2.5 kg 1174 (84.3) 448 (81.5) 726 (86.2)
1.5−2.5 kg 173 (12.4) 78 (14.2) 95 (11.3) 0.08
<1.5 kg 45 (3.2) 24 (4.4) 21 (2.5) 0.04
Median duration of pregnancy (weeks) 39.14 39.00 39.14
IQR 38.00–40.14 37.71–40.14 38.00–40.29 0.23
Duration of pregnancy (weeks)
>37 1188 (85.3) 454 (82.5) 734 (87.2)
<37 165 (11.9) 74 (13.5) 91 (10.8) 0.09
<32 39 (2.8) 22 (4.0) 17 (2.0) 0.02
Perinatal death (n, %)
No/unknown 1374 (98.7) 546 (99.3) 828 (98.3)
Yes 18 (1.3) 4 (0.7) 14 (1.7) 0.30
Gender
Male 717 (51.5) 283 (51.5) 434 (51.5)
Female 674 (48.4) 267 (48.5) 407 (48.3) 0.96
Unknown 1 (0.1) 1 (0.1) 1.00
 P-values were calculated using chi square
Table 2 abbreviations
cART: combination antiretroviral therapy; SGA <10th: Small for gestational age <10th percentile; SGA <5th: Small for gestational age <5th percentile; IQR:
interquartile range
https://doi.org/10.1371/journal.pone.0191389.t002
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Table 3. Risk of babies being born SGA<10th percentile, by univariate and multivariate analysis, using a generalized estimation equation.
Total SGA Univariate analysis
OR (95% CI)
P-
Value
Multivariate analysis
OR (95% CI)
P-
Value1392 33 (%)
Initiation of cART
Postconception 842 181 (21.5) 1 1
Preconception 550 150 (27.3) 1.40 (1.11–1.80) 0.01 1.35 (1.03–1.77) 0.03
Type of cART regimen
PI-based 928 215 (23.2) 1 1
NNRTI-based 438 105 (24.0) 1.04 (0.80–1.16) 0.76 0.95 (0.71–1.27) 0.73
Both/NRTI only 25 11 (44.0) 2.51 (1.16–5.53) 0.02 2.11 (0.98–4.57) 0.06
Age at delivery
1.01 (0.99–1.04) 0.21
BMI
0.99 (0.95–1.03) 0.59
Maternal CD4+ concentration at delivery (cells/μl)
500 738 181 (24.5) 1
200−500 570 128 (22.5) 0.89 (0.69–1.16) 0.39
<200 60 15 (25.0) 0.97 (0.53–1.77) 0.91
Nadir maternal CD4+ concentration (cells/μl)
500 258 56 (21.7) 1
200–500 643 156 (24.3) 1.17 (0.81–1.72) 0.39
<200 cells 491 119 (24.2) 1.19 (0.80–1.75) 0.38
Region of origin
SSA 853 206 (24.2) 1 1
W. Europe 288 55 (19.1) 0.73 (0.52–1.04) 0.08 0.76 (0.54–0.92) 0.13
Other 251 70 (27.9) 1.19 (0.85–1.85) 0.31 1.17 (0.84–1.63)
Smoking status
No 643 156 (24.3) 1
Yes 114 27 (23.7) 0.94 (0.75–1.55) 0.68
Unknown 635 148 (23.3) 0.98 (0.76–1.27)
Alcohol use
No 664 165 (24.8) 1
Yes 75 18 (24.0) 0.95 (0.54–1.67) 0.40
Unknown 653 148 (22.7) 0.92 (0.72–1.19) 0.46
Illicit drug use
No 718 188 (26.2) 1
Yes 21 7 (33.3) 1.49 (0.56–3.74) 0.40
Unknown 299 68 (22.7) 0.89 (0.64–1.23) 0.46
Parity
Primipara 477 93 (19.5) 1 1
Multipara 915 238 (26.0) 1.45 (1.12–1.89) 0.005 1.38 (1.06–1.79) 0.017
Mode of delivery
Spontaneous labour 619 159 (25.7) 1
Primary (elective) C-section 189 36 (19.0) 0.70 (0.47–1.03 0.07
Secondary (emergency) C-section 198 45 (22.7) 0.80 (0.55–1.16) 0.25
Other/unknown 386 91 (23.6) 0.89 (0.66–1.19) 0.42
HIV RNA concentration (copies/ml)
(Continued)
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(12.8%); as a result, the risk of a PTD was 1.38 times greater among women who took cART
prior to conception vs those who took cART afterwards (95% CI 1.02−1.85, p = 0.04, univari-
ate analysis). The same comparison, but taking into account type of cART regimen, maternal
age, CD4+ cell count at delivery, trough CD4+ cell count, region of origin, smoking and illicit
drug use showed that the risk of a PTD was 1.39 (95% CI 0.99−1.94, p = 0.06). Smoking and
mode of delivery were significantly associated with PTD in multivariate analysis after stratifi-
cation for cART drug regimen (S2 Table).
VPTD (<32 weeks) occurred in 0.6% of neonates from HIV-negative women compared
with 2.8% from HIV-positive women. The rate of VPTD was significantly higher among
women who had received cART prior to conception (4.0%) compared to those receiving cART
after conception (2.0%, p = 0.02) (Table 2). The same comparison, corrected for type of drug
regimen, maternal age at birth, region of origin, smoking, illicit drug use, CD4+ cell count and
delivery mode, did not reveal any significant differences between the two groups (OR 1.25,
95% CI 0.86− 1.86, p = 0.22) (data not shown in the tables).
Table 3. (Continued)
Total SGA Univariate analysis
OR (95% CI)
P-
Value
Multivariate analysis
OR (95% CI)
P-
Value1392 33 (%)
<500 947 230 (24.3) 1
>500 426 98 (23.0) 0.79 (0.56–1.10) 0.16
 P-values were calculated using a logistic regression model including generalized estimating equations (GEE)
Table 3 abbreviations
OR: odds ratio; cART: combination antiretroviral therapy PI: Protease inhibitors; NNRTI: Non-nucleoside reverse-transcriptase inhibitors; NRTI: nucleoside reverse
transcriptase inhibitors; BMI: body mass index; SSA: Sub-Saharan Africa; W. Europe: Western Europe; C-section: Caesarean section; Prim. C-section: primary
Caesarean section (elective); Sec. C-section: secondary (emergency) Caesarean section
https://doi.org/10.1371/journal.pone.0191389.t003
Table 4. Risk of a baby being born SGA<10th percentile. Multivariate analysis using a generalized estimation equation and stratified for PI- and NNRTI-based cART
regimens.
PI-based NNRTI-based
Multivariate P-
Value
Multivariate P-
ValueSGA (%) OR (95% CI) SGA (%) OR (95% CI)
Total (n) 928 438
Initiation of cART (n, %)
Postconception 138 (20.9) 1 42 (24.0) 1
Preconception 77 (28.6) 1.49 (1.08, 2.10) 0.02 63 (24.0) 0.97 (0.62, 1.52) 0.9
Region of origin
SSA 126 (23.2) 1 74 (25.1) 1
Western Europe 36 (18.0) 0.73 (0.48–1.12) 0.2 18 (21.2) 0.85 (0.46–1.56) 0.6
Other 53 (28.6) 1.31 (0.89–1.92) 0.2 13 (22.4) 0.81 (0.40–1.68) 0.6
Parity
Primipara 64 (19.3) 1 26 (19.0) 1
Multipara 151 (25.3) 1.32 (0.96–1.82) 0.09 79 (26.2) 1.63 0.07
P-values were calculated using a logistic regression model including generalized estimating equations (GEE)
Table 4 abbreviations
OR: odds ratio; cART: combination antiretroviral therapy PI: Protease inhibitors; NNRTI: Non-nucleoside reverse-transcriptase inhibitors; SSA: Sub-Saharan Africa
https://doi.org/10.1371/journal.pone.0191389.t004
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Discussion
Main findings
In our study of pregnant HIV-positive women receiving cART, the overall risk of SGA was
23.8%. By contrast, among the Dutch HIV-negative Generation R population, the overall risk
of SGA was far lower (1.8%); similarly in the women of SSA origin (1.4%). The risk of SGA
was significantly higher among women who had received cART prior to conception (27.3%)
compared with those who had only begun taking cART after conception (21.5%). The risk of
SGA was also higher among women (n = 928) receiving a PI-based cART (28.6%) prior to con-
ception compared with those receiving the PI-based regimen after conception (20.9%,
p = 0.01). In women receiving an NNRTI-based regimen (n = 438), however, there was no dif-
ference in the risk of SGA whether or not they received the regimen pre- or post-conception
(24.0% vs 24.0%, p = 0.99).
SGA and cART exposure
Few data exist describing a potential link between SGA and HIV infection, cART and PI-based
regimens [7–11]. Of the studies which do exist, the data do not demonstrate any consistency
[7,8,9,11]. One study found an increased risk of SGA in HIV-positive women who were not
receiving cART [10].
Aaron et al.’s study, in the US, supports our findings. Among a cohort of 183 pregnant
HIV-positive women, comprising 117 women receiving PIs and 39 receiving NNRTIs, there
were high rates of SGA (<10th percentile, 31.2%) and (<3rd percentile, 12.6%). In Aaron
Table 5. Neonatal outcomes stratified for PI- and NNRTI-based regimens and based on whether cART was started before or after conception.
Women receiving PI-based
cART regimen
Women receiving NNRTI-based
cART regimen
Total
(n = 928) (%)
Pre-
conception
(n = 269) (%)
Post-
conception
(n = 659) (%)
P-
value
Total
(n = 438) (%)
Pre-
conception
(n = 263) (%)
Post-
conception
(n = 175) (%)
P-
value
SGA
No 713 (76.8) 192 (71.4) 521 (79.1) 333 (75.6) 200 (76.0) 133 (76.0)
Yes 215 (23.2) 77 (28.6) 138 (20.9) 0.01 105 (24.4) 63 (24.0) 42 (24.0) 0.99
Median birth weight (kg) 3.08 3.02 3.1 0.03 3.14 3.14 3.11 0.91
IQR (kg) 2.715–3.399 2.605–3.365 2.770–3.425 2.698–3.44 2.69–3.405 2.7–3.5
Birth weight (n, %)
2.5 kg 791 (85.2) 222 (82.5) 569 (86.3) 362 (82.6) 213 (81.0) 149 (85.1)
1.5−2.5 kg 114 (12.3) 40 (14.9) 74 (11.2) 0.12 55 (12.6) 34 (12.9) 21 (12.0) 0.68
<1.5 kg 23 (2.5) 7 (2.6) 16 (2.4) 0.80 21 (4.8) 16 (6.1) 5 (2.9) 0.11
Median duration of pregnancy (weeks) 39.00 39.00 39.00 0.61 39.14 39.14 39.57 0.05
IQR 38.0–40.1 37.9–40.0 38.0–40.1 37.8–40.3 37.7–40.3 38.0–40.4
Duration of pregnancy (n, %)
>37 weeks 801 (86.3) 224 (83.3) 577 (87.5) 365 (83.3) 216 (82.1) 149 (85.1)
32−37 weeks 104 (11.2) 35 (13.0) 69 (10.5) 0.20 58 (13.2) 36 (13.7) 22 (12.6) 0.68
<32 weeks 23 (2.5) 10 (3.7) 13 (2.0) 0.10 15 (3.4) 11 (4.2) 4 (2.3) 0.27
 P-values were calculated using Mann-Whitney and Chi square tests.
Table 5 abbreviations
IQR: interquartile range; SGA: small for gestational age; cART: combination antiretroviral therapy PI: Protease inhibitors; NNRTI: Non-nucleoside reverse-transcriptase
inhibitors
https://doi.org/10.1371/journal.pone.0191389.t005
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et al.’s cohort, SGA was found to be associated with HIV disease severity, as well as with high
rates of cigarette smoking (38%) and illicit drug use (35%). Women taking NNRTIs were less
likely to have SGA infants below both the 10th and the 3rd percentile [7]. Most of the women
receiving NNRTIs (74.9%) initiated cART during pregnancy, in contrast to our population.
There was no significant association between SGA and cART initiated prior to pregnancy
(25% of the cohort) or during pregnancy (p = 0.052). This could have been a power-problem
due to small amount of women (46) women who started cART prior to conception. With a p
value of p = 0.052, one could argue that there was a trend towards significance. Chen et al.
found that SGA occurred at an overall rate of 18% among their population of 9504 pregnant
HIV-positive women from Botswana and at a rate of 26.1% among those women who had
begun cART prior to pregnancy and continued with it during pregnancy (n = 2851 on
NNRTIs and n = 312 on PIs) [9]. Consistent with our findings, Chen et al. found a higher rate
of SGA in HIV-positive women. They also found that women who initiated cART prior to
pregnancy and continued with it during pregnancy had a higher risk of their infant being SGA
(OR 1.3, 95% CI 1.1−1.5). In contrast to our findings, both CD4+ cell count and maternal
hypertension were significantly associated with SGA. We found no association between SGA
and CD4+ cell counts measured either at delivery or at nadir level. In total, 13.6% of CD4+ cell
counts from all the women in Chen’s cohort were below 200 cells/μl compared with just 4.3%
of recorded CD4+ cell counts in our cohort. This could, in part, account for the lack of associa-
tion in our cohort; with a median of 520 cells/μl our cohort appears to be immunologically
stronger. Also consistent with our data, is a US cohort of 604 pregnancies among 477 HIV-
positive women, with 222 women receiving PIs and 78 NNRTIs. This study also demonstrated
a high rate of SGA infants below the 10th percentile (26%). Phiri et al. concluded that exposure
to a PI during the first trimester of pregnancy actually lowered the risk of SGA (OR 0.54, 95%
CI, 0.29−1.01) compared to non-PI-exposure throughout pregnancy [11]. This cohort was
restricted to HIV-positive women who were eligible for Medicaid who were either multiparous
or had disabilities and who represented the most disadvantaged population [11].
A French study (Briand et al.) investigated a cohort of 8192 singleton neonates, between
1990 and 2006, comprising 2630 women on PIs and 508 on NNRTIs. In contrast to our find-
ings, no significant association was found between the type and duration of cART and the pro-
portion of SGA infants (4%) [8]. However, Briand et al. did not compare cART that was
initiated either before or during pregnancy.
SGA and initiation of cART prior to conception
The cART regimens used in the above studies involved NNRTI-based and PI-based regimens,
and most found an association between initiation of NNRTI prior to conception and risk of
SGA [9]. The studies of Phiri and Briand did not define their populations by use of cART prior
to conception [8, 11].
One hypothesis for reduced fetal growth, resulting in SGA, may be placental insufficiency
due to vascular damage caused by HIV infection or cART-triggered endothelial injury [19].
Whether a specific cART regimen reduces endothelial injury associated with HIV infection or
actually contributes to further endothelial cell activation is still unknown [20]. In our popula-
tion, most women, whether they were receiving NNRTI- or PI-based regimens, had viral sup-
pression, and only 4.3% of all women had a CD4+ cell count below 200 cells/μl. Our finding
that cART initiated prior to pregnancy increases the risk of SGA suggests that cART may have
a specific effect on fetal growth during the first trimester. One possible cause of adverse preg-
nancy outcomes on growth may be changes in the HIV-positive mother’s cytokine profile due
to the influence of cART [9]. Chen et al. comment that successful pregnancy maintenance and
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HIV infection are both associated with Th type 2 cytokine predominance. As cART acts to
reverse Th type 2 to Th type 1 cytokine predominance, this conversion could result in the
modification of cytokine levels and immune milieu that may influence pregnancy outcome.
PIs are highly protein-bound and subject to backward transport through P-glycoprotein, so
any adverse effects on fetal growth in utero cannot be explained by placental transfer, which is
minimal or even non-existent [21]. A recent study on sex steroid hormones offered another
hypothesis for exposure to PI and SGA [22]. Progesterone is essential for maintenance of preg-
nancy. Low levels have been associated with an increased incidence of pregnancy loss, placen-
tal abnormalities, prematurity and fetal growth restriction. These placental abnormalities
could endanger fetal growth. Certain PIs, but not NNRTIs, cause reduced progesterone levels
in vitro and in a pharmacological mouse model. Progesterone levels were also found to be
lower in HIV-infected pregnant women receiving PI-based cART compared with uninfected
controls. Lower progesterone levels correlated with fetal growth restriction in both the mouse
model and in HIV-infected patients. In vitro trophoblast progesterone production was signifi-
cantly reduced by lopinavir, atazanavir and ritonavir exposure, but not by darunavir [22].
We found that women who started on cART prior to the onset of their pregnancy had several
differences in baseline characteristics (were older, a larger proportion had a CD4+ cell count
below 200 cells/μl at time of cART initiation, were more often multiparous and more likely on
an NNRTI regimen compared to women who started cART in pregnancy). Women on cART
prior to pregnancy could have been in a more advanced disease stadium. Therefore, confound-
ing could not be completely ruled out even though individual characteristics were corrected for
in multivariate analyses. Neither median nadir CD4+ cell count nor median CD4+ cell count at
the time of delivery were associated with an increased risk of SGA. This suggests that immuno-
deficiency is not the main cause of SGA as suggested in the paper by Aaron et al. [7].
Preterm delivery. Our study found a non-significant increased risk of PTD if cART was
initiated prior to conception; PTD was also higher among women who smoked (multivariate
analysis).
Previous studies on adverse birth outcomes related to cART use are diverse and the con-
flicting results may, in addition to the cART regimens used, be related to different populations
at different disease stages, different settings (developed or resource-limited countries), limited
access to cART regimens, small population numbers, lack of an HIV-negative control popula-
tion and incomplete data [3, 4, 12, 14, 15, 23–28].
The strengths of this study were the detailed baseline demographic and clinical data recorded
from a well-characterized large population in the ATHENA cohort. Our large sample of HIV-pos-
itive women allowed us to perform this research and to stratify for cART regimen used. Selection
bias was not likely to occur as women from all social, ethnic and economic backgrounds have the
same access to healthcare in the Netherlands. Women with other risk factors for SGA infants,
such as illicit drug use, alcohol consumption or cigarette smoking, were in a minority. Our study
has several limitations, mostly related to the retrospective nature of the study, resulting in missing
data on smoking, substance abuse and socioeconomic background. This study covered several
years of observation. Over time the guidelines for cART initiation changed and were based on dif-
ferent CD4-cell count levels. Fewer women were receiving an NNRTI-based regimen so the
power to detect differences was reduced, so the finding of no significant association between SGA
and preconception use of NNRTI may, in part, be due to sample size.
Conclusion
In summary, our data showed that initiation of cART prior to conception is associated with an
increased risk of SGA while cART initiated post-conception is not. When stratifying for cART
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regimen, this risk was clearly seen among women receiving PI-based regimens prior to con-
ception who constituted the largest group. cART initiated prior to conception also revealed a
trend towards significance in the increased risk of PTD.
As most of the current HIV guidelines advise initiating antiretroviral therapy at any
CD4+ cell count, the number of pregnant cART users, who began their regimen prior to
conception, will increase. Studies performed in this new population will be help to see if
pre-conception cART and which regimen is the critical factor in the adverse pregnancy out-
come. While the clinical benefits of cART regimens in HIV-infection and for PMTCT are
clear, there remain risks for cART use prior to conception and during pregnancy [1, 29] which
need further investigation. Further research involving larger cohorts of NNRTI users, who
began their treatment prior to conception, is needed to clarify the potential association with
SGA.
Fetal growth restriction, resulting in SGA, is a serious condition with increased morbidity
and mortality, including neuro-developmental delay, as well as hypertension, obesity and dia-
betes mellitus in adulthood [30]. More information about the mechanisms underlying fetal
growth restriction in HIV-infected pregnant women using cART is needed. Only when the
potential impact of cART is fully understood can we determine the optimal individualised reg-
imen for HIV-infected women of childbearing age.
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